BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 21931540)

  • 1. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
    Suppiah V; Gaudieri S; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Hellard M; Riordan S; Matthews G; Sheridan D; Nattermann J; Smedile A; Müller T; Hammond E; Dunn D; Negro F; Bochud PY; Mallal S; Ahlenstiel G; Stewart GJ; George J; Booth DR;
    PLoS Med; 2011 Sep; 8(9):e1001092. PubMed ID: 21931540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.
    Knapp S; Warshow U; Ho KM; Hegazy D; Little AM; Fowell A; Alexander G; Thursz M; Cramp M; Khakoo SI
    Gastroenterology; 2011 Jul; 141(1):320-5, 325.e1-2. PubMed ID: 21600205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan.
    Nozawa Y; Umemura T; Joshita S; Katsuyama Y; Shibata S; Kimura T; Morita S; Komatsu M; Matsumoto A; Tanaka E; Ota M
    PLoS One; 2013; 8(12):e83381. PubMed ID: 24349500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
    Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
    Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.
    Vidal-Castiñeira JR; López-Vázquez A; Díaz-Peña R; Alonso-Arias R; Martínez-Borra J; Pérez R; Fernández-Suárez J; Melón S; Prieto J; Rodrigo L; López-Larrea C
    J Virol; 2010 Jan; 84(1):475-81. PubMed ID: 19846535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population.
    Shan Z; Huang J; Liao Q; Huang K; Wang M; Xu R; Tang X; Zhang W; Nelson K; Fu Y; Li C; Rong X
    Transfusion; 2018 Apr; 58(4):1028-1035. PubMed ID: 29446443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.
    El Awady MK; Bader El Din NG; Tabll A; El Hosary Y; Abdel Aziz AO; El Khayat H; Salama M; Abdelhafez TH
    World J Gastroenterol; 2013 Jan; 19(2):290-8. PubMed ID: 23345953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
    Jung YK; Kim JH; Ahn SM; Yang JW; Park SJ; Kim JW; Yeon JE; Kwon OS; Kim YS; Choi DJ; Kim JH; Byun KS
    J Clin Gastroenterol; 2013 Aug; 47(7):644-50. PubMed ID: 23442843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population.
    Dong ZX; Zhou HJ; Xiang XG; Guo SM; Zhuang Y; Zhao GD; Xie Q
    J Dig Dis; 2015 Feb; 16(2):90-7. PubMed ID: 25312023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of IL28B rs12979860 and rs8099917 Genotypes in Patients with Chronic Hepatitis C Virus Infection in Tianjin, China.
    Qiao K; Trieu C; Huo Z; Du Y; Hou W
    Clin Lab; 2018 Apr; 64(4):543-550. PubMed ID: 29739095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome.
    Vidal-Castiñeira JR; López-Vázquez A; Martínez-Borra J; Martínez-Camblor P; Prieto J; López-Rodríguez R; Sanz-Cameno P; de la Vega J; Rodrigo L; Pérez-López R; Pérez-Álvarez R; López-Larrea C
    PLoS One; 2014; 9(6):e99426. PubMed ID: 24927414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
    Lin CY; Chen JY; Lin TN; Jeng WJ; Huang CH; Huang CW; Chang SW; Sheen IS
    PLoS One; 2011 Mar; 6(3):e18322. PubMed ID: 21479134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.
    Akkarathamrongsin S; Payungporn S; Thong VD; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
    World J Gastroenterol; 2014 Aug; 20(30):10599-605. PubMed ID: 25132781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
    AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.